Welcome everyone and good morning and good afternoon depending on where you are um I'm uh happy to kick off the inaugural uh priia uh webinar series for the year and our first one uh with Medtech Trends to watch in 2025 through the lens of reimbursement and Market access just a quick introduction to myself and I'm joined with my esteemed panelist here and colleagues from priia who will introduce Themselves um I'm Executive Vice President of reimbursement Health economics and Market access and corporate development here at priia um I have been in the reimbursement Health policy space
for just about 30 years and um have extensive experience in really helping new and novel uh Technologies and and innovators market and commercialize their Technologies by establishing uh reimbursement and Market access uh for patients who can benefit From these Innovative therapies I've been a consultant for over 15 years about 12 and a half years at Johnson and Johnson and I'm also a judge and value framework um uh facilitator for several um uh innovator innovator a Medtech innovator and creative destruction Labs as well as some biodesign groups and a consultant for again many Medtech companies and
um incubator programs if for those of you who don't know who priia Healthcare is just a Quick introduction of what we do we are a full Services reimbursement and Market access consulting firm Services firm uh really focused on the US and ideally we're helping clients very early on with a full Suite of services through strategic product planning so really understanding the market not only the total addressable Market but the serviceable addressable Market taking a deep dive into that uh we also support a reimbursement strategy understanding the Coding coverage and payment for a new and novel
technology and implementing that throughout the product life cycle we also provide clinical trial support programs so those are for technologies that are in a clinical trial phase and helping principal investigators gain reimbursement during those trials we have an advisory Council which we're really proud to um to have on our team as an extension of our team of experts in the industry so these are individuals In the ecosystem who are former medical directors they represent value analysis committee uh Committees of hospital so those are the buyer typically of of these new and novel Technologies and also
coding advisors and we also have a specialty Global specialty uh network of Specialty Physicians across the across the globe we also have patient access platform Solutions so we offer hotlines billing and coding hotlines um and also patient access programs to the industry And we also work uh very act we're very active with payer engagement so we work with the payers across the country who really determine whether or not not these new and novel Technologies are medically and reasonable and necessary so with that I'm going to um let my esteemed panelists introduce themselves starting with Kelly
PTI hi nice to meet everyone Kelly Puchi uh I'm the Executive Vice President of Operations and strategy for priia uh I Like Tanya have been in the industry for over 25 years have uh really worked in many different fragments everything from Pharmaceuticals DME uh Diagnostics um have been really excited to join pren this last year and helping many multiple uh organizations figure out how coding coverage and payment set a great foundation for their commercial strategy looking forward to today's discussion thank you Kelly next Ryan Nolan hello everyone my name is Ryan Nolan I'm the senior
director of reimbursement Health economics and Market access at priia uh it's a pleasure to be here today to talk with everybody and uh join my esteemed colleagues uh in short I am a former biomedical engineer and entrepreneur wherein I led the clinical trials and reimbursement for the better part of a decade and then decided to join the priia team to help other Companies to similar success thank you Ryan Christopher en roll hello uh thanks for having me Tanya uh I'm looking forward to the conversation today as a lot of lot of interesting issues if I
wasn't on the panel I'd certainly be be tuned again so I am the director of compliance uh reimbursement Health economics and Market access for priia and uh I'm one of the newer additions to the priia team I actually came over with the absorption of our Jens advisers uh last quarter and it's been been really great working here with the team and and getting to know some of the the great personalities we have so I am uh I'm an attorney by training uh and what I do primarily here is I help priia and its clients really
dig into to Tactical issues related to advocacy and and claims and and coverage and because I am an attorney I need to throw a disclaimer out that nothing I'm Saying at this meeting here should be taken or construed as specific legal advice um we're just here having an academic discussion so thank you academic and pragmatic discussion right Chris and uh absolutely Chris's role is imperative here at PRI um because compliance uh is very is critical when we talk about reimbursement and Market access so thank you Chris last but certainly not least Tracy Davis hi all
thank you so much for Joining today looking forward to the discussion um I've spent the past uh 20 years with a focus on novel therapies for Pediatrics and nephology um I've I've worked with molecular Diagnostics and startup Med devices um trying to get get patients covered um I started my career off as a clinician where I sat on the other side of the desk pushing for patients um to get approvals for for key therapy so thank you so much for having me Today great thank you Tracy and thank you and and um you know again
this is a very um really a dialogue and an informal conversation um but really again looking through the the trends in 2025 and even Beyond in terms of Medtech and medical devices in particular and what we're seeing again with the lens through the lens of reimbursement considerations and Market access so um I just want to kind of Tee It Up here with the some investment Trends and we would Be um negligent if we did not mention our great friend uh AI artificial intelligence it seems to be the hot buzzword around um all Industries um with
you know Medtech not being an exception here but the global AI Healthcare market and this was stunning to me was valued at approximately $19 billion in 2023 and is projected to grow at a comp compounded annual growth rate of 38 a half% from 2024 to 2030 I think that's an astounding number I'm not sure If uh others agree but uh certainly AI is here to stay and has been around for um for a very long time but now you know consumers are able to use Ai and it's being really integrated into many clinical applications so
diagnostic it's used for drug development to expedite drug development decision support tools and systems and Predictive Analytics so uh really you know a great Focus here on on AI and those Technologies um minimally invasive and Robotic surgery when I was W with Johnson and Johnson previously we um had a very big focus on laparoscopic surgery who would ever thought that a you know that a that a surgery could be done through a a you know five inch incision but it is and then we've got robotic surgery really um Da Vinci's been the main you know
the main the main one uh for many many years but we've got a lot of competition coming into the market and then we've Got of course wearables and remote patient monitoring which really catapulted you know were catapulted during the co era but but you know just taking these kind of investment Trends into account and looking at from again that lens of reimbursement in Market access um you know we often work with investors who are um evaluating I would say the reimbursement Readiness and Market access Readiness of specific technologies that we work on and and Would
love to hear from the panelist um what specific Trends or red flags or considerations um have you seen in your working with your clients and our clients um in terms of of you know investment Trends and working with investors um what would you impart on the audience maybe I'll start with Ryan on that one happy to um the that's a that's a big question um I think that uh from the investor side Of the equation um especially over the last you know 10 even five years there's been a increase in terms of education and awareness
on the reimbursement side of the spectrum um investors are getting wiser to uh speak to some of these key areas that are crucial to commercial success and so from a entrepreneur perspective you know one of the things that we try to help our clients with and that I would just generally advise if I were to Let's say Do It All Over Again would be to really focus in on not just the technological innovation and you know hitting all your your pretty standard Milestones like when are you going to hit FDA but really diving into do
I have a firm understanding in of the market in which my technology is um going to integrate and then what are some of the reimbursement constraints um or better yet who is the financial stakeholder a lot of the uh investor activity and um Education of late has been around you know is this a traditional reimbursement play or is this something that's more of a hospital acquisition play uh within the existing payment mechanisms is it something that it's truly novel that doesn't have a benefit category and what do you do in those circumstances and you know
investors are asking really challenging questions that I would counsel entrepreneurs to to partner with uh expert in the space uh consultant Etc That could help with um formulating a plan if you know no matter how early to to prepare you to be able to speak to those questions intelligently yeah thank you for that and and Kelly you were at um JP Morgan what um what were you hearing in terms of um invest Investments and from the investors yeah I think um I think the critical part from an investor perspective is how does reimbursement help me
commercialize right so how does Coding coverage and payment essentially make our our opportunity for a technology to get adopted um and I think to really understand that or to help companies help investors invest at the right time or understand the Milestones as Ryan so eloquently said is really understanding who do we need to be talking to and when do we need to be talking to them I think Ryan gave a great example of the FDA I think a lot of times where um the reimbursement Consulting can come in is how soon can we also be
talking and planning out your reimbursement strategy at the same time as your regulatory strategy why those two things are intricately linked is sometimes I think uh Tanya your question was part about red flags is we only focus on one stakeholder at a time meaning I only set up my clinical trial to talk to the FDA when we could be using that money little call it a little bit more wisely where we could be Talking to multiple multiple stakeholders within the same opportunity to develop ele uh evidence so my recommendation a lot of times when we're
we're meeting with different stakeholders investors and alike is really understanding how does the reimbursement strategy catabol the commercial strategy and how do we make sure that when we you know plan and invest in a technology from the beginning how can we be thinking about The number of resources that we need to put into that technology clinical studies the one to leverage that over essentially the the life of the brand and the long-term outcomes that we're looking to measure right yeah and I'll add to that one thing that gets missed oftentimes in the early process of
startups is aligning favorable reimbursement with sales geographies and so investors are looking for more conservative approach To investing in the commercial sales team and and it should be looked at in alignment with Market access so that the money is spent wisely and can establish proof of concept and favorable reimbursement early on great thank you Tracy those those are great comments um you know we we there are some specific challenges as it relates to digital health and AI Technologies um from a pure reimbursement standpoint because there Is no benefit category that's recognized by CMS um what
what specific considerations um should investors have when they invest in in you know technologies that are AI specific or digital Health um and um you know have we seen any um exceptions to the rule of not having you know not having a benefit category out there maybe Chris if you could provide your comments or or anyone else here on that one Chris you might be muted as Well sorry there we go yeah that that's absolutely always a challenge um because there's there's certainly uh a challenge that comes up with trying to get 2025 Technologies to
fit into uh a benefit category structure that comes from the the 1960s maybe the 19 either way before I was born despite the fact that I've a a significant amount of gray in my beard at this point and that uh a lot of times the the best way to look at that is is looking at the fundamentals and just Really looking at what um what the technology is specifically doing to improve the care pathway and that if you start with the good fundamentals working with some of those specific challenges becomes way more approachable and there
are some precedents out there from from for doing that which we in a really great presentation like this that Ryan had done a couple months ago yeah absolutely and I think viz aai In particular if folks are familiar with that technology um they did receive a new technology add-on payment with CMS a few years ago and I think they kind of broke that you know both that mold and are the exception to the rule of of an air related technology in a space that was you know very much needed so there was a clear unmet
need and there was an exception made there so looking for those I think will be important as we move forward you know we talk a lot About um value propositions um but we've I know as a collectively as a team we've talked a lot about the value proof how do you think that interplays with the um investors out there in terms of how you might have seen changes and the evolution of what investors are willing to invest in um are they are they really looking at the value proposition or do they now want the proof
any thoughts on that from the Panelists uh I can jump on that so I think historically speaking um most of the if we're looking at you know Acquisitions or uh an exit strategy say for a investment opportunity a lot of what I think investors are starting to focus in on is not just you know can this get through FDA and then get acquired immediately or shortly thereafter um I would would say in general gone are the days of that Kind of acquisition behavior and in re in reality a lot of the bigger fish in the
pond as it were are looking for can you show me commercial traction can you prove out your reimbursement plan in practice through some of these you know maybe um additional payment methodologies or or um other avenues to really prove out that this is a viable business model before acquiring in Medtech um so I think the investment mindsets Kind of Shifting as a result of that to not just expecting a a quick acquisition post FDA and and looking really into what are the variables that are going to drive that valuation and acquisition Downstream uh with more
of that timeline in mind yeah I love I love what you said there Ryan and I I love the word proof uh I think from an investor Community right I've seen so many times s uh where maybe we get really good coverage but Then yet right where's the pull thr on adoption or maybe we don't have great coverage and yet we see commercial ramp I think it's when we marry kind of all the above that we see what we would call proof I.E the efforts that we put in towards getting let's say a pair to
coverage in the Texas market now has you know seen stronger adoption now that we have that coverage in place same with like confirmation of payment it's great if a fee schedule has just been Published but how do we then go back and confirm that Physicians and hospitals are being paid as appropriate to that fee schedule that's been published so it's one thing to have something done it's another thing to watch that thing that's been like proven or succeeded turned into proof of success I.E how did we take this win and how did we pull it
through in order to get that commercial effect and I think that's one of the thing that things that we see happening In this market as Tanya has addressed is we don't want to just know that Something's Happened we want to know that it happened and that it worked and that if we look to exit as Ryan said or right in in any way whether that's um you know acquisition or or going public that we can multiply the effect if we've seen it once twice three times that we could build this out to a hundred sales
folks and so I really think that's where the proof comes in is saying hi we have This Milestone we've intentionally planned for it regarding their coding coverage and reimbursement and based on those wins this is now what we can anticipate and this is how we'll grow this Market moving forward again just to make it a little bit more tangible for folks rather than just something or Milestone that we've seen but rather proof that this Milestone led to better adoption absolutely and I think there's there's a there's a a desire to drisk as Much as possible
so you know perhaps the um it's less and less as far as I've seen um as of late it's less and less about we're going to acquire or even as a strategic invest in the technology before even FDA approval or clearance is obtained um but they want to see is there can you really Market this and um and really the proof of concept which is what we're we're really talking about great oh go ahead I was just gonna add that um you know to add on to Kelly's Point um I think some of that value
proof is obviously through your clinical trials and then your early commercialization success but um there's a lot of a a comparison also to um can you provide me comparables uh in terms of other companies that are have journeyed on the path that you know your let's say a specific company's current trajectory um is aimed towards can you show me other companies that have set some sort of precedent to give me some Confidence or you know proof in a way um so it's not just purely uh what you've done but also you know trying to be
more educated or aware of uh what are some of the precedents that may be applicable but it's important to note and I think that a lot of investors are starting to key in on not just can you provide me a comparable but what are the differences um you know what are some of the risks that this investment opportunity may Have that are different from the comparable that you're describing yeah absolutely thanks everyone for those that great input very insightful just kind of Switching gears now to um some a topic that we talk about internally amongst
the team here um quite often and with our clients is the increased enrollment in Managed Medicare um in 2024 over 50% of the Medicare beneficiary population was Enrolled in a Managed Medicare plan or known as part C is in cat um and that is increasing and it's not definitely not not going to be slowing down so what this means essentially is these patients are managed by a commercial payer and not CMS or the Medicare contractors um and you know again not to belabor all of the details here on the slide but I think this slide
represents and shows depending on who you ask that we expect in 2030 for the Medicare Medicare Beneficiary population to be over 60% in a Managed Medicare Plan I personally think it will be higher but again it's depending on who you ask and and the reasons for these um you know this this growth driver is these Managed Medicare plans offer um substantial benefits that are not provided under a traditional Medicare Plan such as you know Dental um benefits silver sneakers a gym benefit um over-the-counter supplies there's oftentimes zero Premiums or or no deductibles um you know
uh and and there's just Financial incentives also for Brokers to sell these plans honestly so um with respect to Medicare Advantage uh plans and the growth thereof um I'd really like to get the panelist thoughts on and considerations and and with Medicare Advantage enrollment increasing how should medical device companies adopt their reimbursement and Market access strategies what do they need to consider To meet the challenges and opportunities of the Managed Medicare model and I know the panelists have lots of thoughts on this so I'm looking forward to very Lively discussion um so whoever wants to
jump in first please uh I can I can jump in on that um and then I would probably want to pass to Chris because I know he has uh some good thoughts on this as well if I could put you on the spot there Chris but um I think you know if I were to kind of set A foundation for the this specific topic is that I think a lot of the industry needs to focus on thinking things through in terms of national coverage determinations or local coverage determinations from Medicare they're very different than coverage
policies and Medicare is not in the practice of you know setting policy really they're focused on how do we set up guard rails to prevent Fraud and Abuse of uh you know particularly wide widely utilized Technology or excessively expensive technology um so with that in mind um Medicare Advantage plans um tend to utilize commercial policies because there's a lot of loopholes in ncds and LCDs they're not meant to be as comprehensive as a a commercial payer policy and um within those gaps uh you know we're seeing sort of a a behavior on the rise and
I don't want to steal your thunder Chris of you know this impacting on a claim by claim basis What's actually covered and paid under a Medicare Advantage plan um so from a strategy perspective with that in mind you know my recommendation would be for companies that know hey the majority of our payer populations going to be Medicare Advantage or commercial you should prioritize what do I got to do to win the commercial payers because the objective across those two is the largely the same and if you're starting from a negative policy what do you need
To do to achieve a positive coverage policy and and you know remove that negative one or if you're working within a silent coverage policy meaning there's not you know anything officially out there your technolog is kind of in a um a novel area um or even you know just in general you should focus on what do I need to achieve um success on a claim by claim basis um in either case I think the answer to all of that is your your Clinical trials your your value proof how are you proving um successfully to those
payers that this is a a technology that's going to change decision-making and therefore change outcomes and costs associated with that so I'll I'll stop talking now uh and step down and let you uh you know add your thoughts Chris because I know that you've got um thoughts from your side of uh priia yeah I could um I could certainly Spend a lot of time talking about this because this is really a pretty big part of my Consulting and advocacy practice um because it it's an issue that's coming up for a lot of the clients that
we have and every time somebody runs into issues related to maos there there's this perception that we we end up having to talk to them through the where they're like well what's gone wrong for us like why do the Medicare Advantage organizations the maos not Like us anymore and uh the good bad news is it's it's not you um it's it's industrywide pressure um and we we're certainly in unique position to see that being um being the largest provider of access programs to Medtech so we get a sample and and one of the broadest experiences
that there are on this and it's it's happening to everybody and to to the point You' raised earlier yeah there are payers who are absolutely bringing in Their commercial policies my position on that is that that is inappropriate and I can tell you that the majority of the administrative law Jud judges agree with me um there are some that don't but this this is becoming a a huge issue for advocacy and in terms of um because I know we're going to talk about this later in terms of how this impact strategy it's to me when
when I look at what's going on with this and and how in 2023 manufacturers and and rather Clients could look and and count that well a fair portion if not most of my medicare Medicare Advantage claims will get paid as long as Medicare is paying and then see the trends that went on in 2024 where those approval numbers took uh an essentially an industrywide nose dive um it it it should be getting everybody's attention and it should be something that people are looking at with a critical eye saying is does the TR does the traditional
kind of toe hold In Medicare build out to Mao then build into commercial does that work um right now or or should we be going with a plan A and A Plan B simultaneously uh my feeling on this is that a plan a and plan B simultaneously is going to make sense for a lot of people but it's not going to make sense for everybody and and that's why it's important to sit down and have conversations with folks like us about it yeah there's also um a proposed part C rule um that could come into
effect in 2026 but it's still subject to political process at this point um it it is more favorable towards patients so we that will play out in the future because this is becoming such a popular issue or problem um but the good news is that manufacturers like priia have Patient Advocates um who can help manufacturers with this and a lot of companies have great internal advocacy programs and we are starting to see um a lot of Overturns of late um especially early on in 201 25 with some of these cases it's a really good point
yeah and um and if if I may there there there's a dispute here between patients and between providers and between these Medicare Advantage organizations and it's really coming down to this phrase which is General coverage positions uh excuse me General coverage guidelines now there's regulatory guidance that says that uh Medicare Advantage organizations have to cover everything that traditional Medicare does if it is um if it is under an NCD LCD General coverage guidelines and um and whether it's under other Medicare Publications uh this proposed rule that Tracy mentioned uh had a significant amount of language
on uh how these words should be interpreted which is why when I look at it I I read it as being fairly prop patient although I know there's Differing takes on it now um it's like with with any legal opinion it's still an opinion people sometimes differ on it but um but it's certainly a potentially big step forward because we take the position that if traditional Medicare is paying for something and they're paying for it on a regular basis they're using general coverage guidelines to make that determination which is is it in a benefit category
is it not otherwise excluded and is it reasonable and Necessary there's other coverage guidelines that appear in some of the program manuals but I'm going to oversimplify it for the purpose of the discussion we're having here and the maos there're taking the position that well that's not General coverage guidelines or other Publications despite the fact that it's all pretty clearly published so that's that's currently the uh the bleeding edge of of advocacy on that those are great points and and with Respect to Medicare you know the insurance largely 465 and over and those with um
anst dral disease how does Medicaid differ as relates to um statutory obligations that they might have to medic Medicaid manage care plans they might have to follow what the state's plan actually covers or pays for are the rules the same well it differs in about 50 different ways um so there there certainly uh National guidance and Medicare certainly provides things for us to look at like the model contract some of the program payment rules but each state tends to operate in a little bit of a different way and and they're under such incredible budgetary constraints
where a lot of these programs are running out of money every year so you can see why there's some variance and they're also subject to local political process in 50 different states so it certainly creates Some some challenges but um but the two uh the two certainly impact each other yeah definitely we have a um um a lot of clients who and and I've seen in the industry um the new technology add-on payments increase in number I think with the Advent um of breakthrough designated devices for from FDA which really makes it easier to obtain
in new technology add on payment which is temporary do those same payment models um apply to Medicare Advantage plans and Kind of what are the pros and cons I guess in considering whether or not you pursue a new technology add-on payment um if they don't apply um so from my perspective uh and what we've seen um in our work is that medic Advantage Plans simply put aren't obligated to recognize or participate in these programs run by by CMS like ntap TPT or new tech APC um and so this kind of comes back to you know
what is what is the exact payer Mix for the patient population that your technology serves or benefits and um you know because of the fact that Ma plans aren't obligated uh you shouldn't necessarily expect them to to pay for these programs so when you're considering applying for these programs I would caution not to look at it as a Milestone or checkbox as it were for raising funds with investors or trying to uh lure a potential acquirer um but rather you need to seriously consider Applicability is this uh actually meaningfully going to impact your Market access
success um and to just kind of add a little bit of some examples to solidify the point for instance if your main patient demographic uh isn't a large portion of the Medicare population I think there it begs the question of whether or not this is appropriate um you know if you're developing a pediatric product for example um furthermore you know if your Product is not predominantly used in the hospital inpatient setting end's probably not appropriate um to the flip side of that coin if your product is not predominantly Hospital outpatient or ASC Centric uh then
transitional pass through a new tech Tech APC um may not be directly applicable to your your commercialization strategy either so um I would you know try to frame this not from a perspective of let's just get Some Milestones checked off but rather what's going to really further our success and um you know highlighting also the fact that we've already talked about you know commercial payers are fast growing to be a predominant payer in the US and if they're not going to recognize any of these programs is your time and funding really efficiently spent pursuing these
things um rather than focusing on conducting the right clinical trials and setting up the right Patient access programs to really effectively launch a product in the market and convince the commercial payers of your value proof not your value proposition yeah thanks for that and just to make a quick announcement um housekeeping I was remiss in letting everybody know who's attending if they have if you have questions we're going to um allocate the last 15 minutes of the webinar to questions from the Audience um please put those in the chat and we will collate those and
address them um at at uh at 45 minutes after the hour um but just to kind of again switch gears and that was great great discussion about Medicare Advantage um and the growth um as it relates to patient access and uh we are priia is the U one of the largest patient access uh Services providers for the med tech industry in the US um what trends in patient Advocacy um have we seen and what are um what are kind of keeping our clients up at night so I'd be happy to to start out on that
one so a lot of what we just talked about in the Medicare Advantage discussion uh is is really creating difficulty for some of our clients um especially with the way it's been such an evolving situation where it it it used to be something that was pretty reliable back when folks were making Their original plans and they've had to adjust on the Fly and so what we discussed about um this is certainly a place where quality of advocacy makes an issue uh or rather makes a difference where where we've been able to see um what's happened
with some clients that haven't had programs versus clients that do have programs it's different for the folks that fight back and I encourage everybody to fight back whether they do it through us or they do it with their Own progr or they do it with another good provider it matters and if if folks aren't sending in appeals and they aren't taking them out to external review or alj then um then the maos aren't going to learn their lesson and it costs them money to go to each level so I had um I did alj hearing
last week where the payer brought five staff an outside attorney and a uh an internal medical director that's not a zero cost meeting for them them so by by making Them go and make letting them know that hey we're not just going to sit down we're we're going to take this we can all make a difference um the other thing that's been been really impacting some of our our well we've been finding techniques to work around it but has been impact impacting the industry at large is what I'm going to call soft denials uh and
uh a good example of this is this whole idea of no prior authorization no predetermined NE Necessary or no prior authorization no predetermination uh available um and and the example of the two of those that we see the most uh is probably the the no prior author no predetermination available one and kind of The Nightmare scenario where this comes up is if you have an office that's just coming online and and they're a new user um they have somebody who's in their office and they're they're checking all these cases that are coming up In whatever
their local EMR or E Benefits check system is and they're putting in the codes they're putting in the patient they're seeing great the patient does have the insurance they say they do let's see if this code needs a prior authorization and they're checking the system and the system saying oh great no prior authorization necessary no predetermination necessary but the part that gets lost is um although this is going to change hopefully in the near Future these systems aren't very smart um and and be it either from every I'm going to think about this optimistically and
I'm going to say that what's going on is everybody including the payers are are just trying to get caught up on how to work with new technology and and be effective in a paperless system uh but these systems are just taking the code that's getting put in by the office and checking it against the prior authorization list and when it doesn't Find the code on the list it dumle comes back and says no PA necessary go right ahead what you're not seeing is on the back end it's not necessarily checking for coverage issues and I
think as we all know that that's sometimes an issue with new technology and typically one of the beach heads for being able to argue and engage in advocacy is getting back a denied prior authorization so if um if this is happening and folks are not staying on Top of it there's really two big problems that come out of it the the first one is you get really frustrated providers because in in that example I gave uh where they just give the thumbs up and say go ahead maybe they do five cases and then they submit
the claims and they all get denied um and in a better situation where they pause um and you have no prior authorization no prior determination you don't necessarily have that organizational determination that You need to launch into appeals and advocacy so there's there's a whole slew of just tools and techniques that we used to work with it but but it is the soft denials are becoming more and more of an issue industrywide yeah absolutely I'd like to add in a little set and I love everything that you said there uh Christopher I think the the
takeaway message is Advocate because you can advocate so that you get the voice of your technology out there Whether those are through the appeals process or just simply by putting in the requests a large number of times when we've been asked to help folks get policies and coverage but one of the first questions of medical director will ask us is who's even using this and have they even tried it right and so if we don't see enough demand from their perspective if you're looking at you know 20 million covered lives and somebody's asked for it
five times maybe It doesn't make sense that they're going to write a whole policy because it is more effective that for them to just look at those five patients so I think it's really important why I think Pria has been so successful in developing this portion of their organization is really based on the fact that it is a foundational requirement to understand how much utilization where that utilization is so that we can help with those other things when we think about Coding coverage and payment I see this as one of those foundational building blocks to
help us get better and smarter about pulling through the winds like we talked about earlier as well as creating leverage so that we can create uh different Milestones like policies to make that access easier and then you use that information right as you acquire it um you know I think Christopher did a great job talking about hey how can we understand when something is right like Maybe not working but even when they are if we see that a payer is consistently approving it like 80 90% of the time and we can understand what is consistent
about that patient demographic that they're sending in is getting approval it's blow hanging fruit for us to then take up the opportunity and say hey there might be a easier faster cheaper way IE creating a policy so it's not as administrative for all organizations in order to help these patients get access So I do I'm a huge fan of advocacy especially when it's come to putting the requests for the technology let you know let different folks like Priya or your organization continue on that path whatever it needs to look like hopefully it's we submit it
the first time and they get approved but if not right what are the additional messages that that payer needs to hear in order to become educated and then see and physically feel the tangible demand that's Happening in the field for that technology are just critical parts of why an advocacy program in my opinion is very critical for medical technology adoption that's great thank you for that feedback Tracy did you have something to add yeah just that it's a it is a complicated issue because with every payer that we work with it's a different medical exception
process for an unmet need and that can be really challenging For Physician Offices to handle on top of their day-to-day workload and I think that's where Priya has also been really successful is we just we process such a high volume of medical exceptions successfully right so kind of on that point we've got a few minutes before we open it up to the Q&A uh which again individuals can put that their questions in the Q&A uh section um given the increasing pressure for utilization Controls over the last few years what tools and best practices can Medtech
companies Implement to ensure patient access while navigating the Waters of healthc care compliance I think this one logically goes to Chris I mean the the starting point is always communication and and working with your team and making sure that everybody understands the importance of um of reimbursement and how it fits into the picture because so much is based on The appropriate sharing of information and it's it obviously needs to be done in a way where all of the boxes for for hipa are being checked but that being able to share information between um what the
issues are and what the realities are for for clinical managers or for reps and what's going on with um with the reimbursement team and what's going on with the advocacy program that that level of interoperability is becoming just more and more necessary And just part of good fundamentals um because having a good ground game and and a good field team makes a big difference but you really got to do it in a way that um that is compliant with this broader framework and I could go on for a long time about this one but uh
but I noticed the clock and I noticed that we promised 15 minutes for questions I did I did want to add if if you were looking to get questions in the tab for doing that is the Q&A bubble It's not the chat bubble uh so if you you look at your window there should be a Q&A bubble right next to the chat one to submit questions that's great yes we are um shockingly almost out of time here so uh we do have um a few questions and one in particular is uh what is the proposed
part C rule we touched on that just briefly I think Tracy with you um for Medicare Advantage can you maybe elaborate a little bit into what that Rule is I mean I'd be happy to hop on that one so um so last month uh CMS put out a proposed program rule for 2026 for the part C program um and in that rule there's a bunch of regulatory updates related to how Medicare Advantage is going to operate now the comment period for that rule already came and went and um Pria some of our clients and MDMA
all took the opportunity to to submit some some really thoughtful comments on that Uh however that was also when uh there was some political process going on and all Ru making got frozen at CMS for a while uh so where we're going to need to see where that goes and How It ultimately comes out on the the other side uh but the rule is available on the um uh the proposed rule is available on the CMS website and the way you'd want to find that is looking for the uh the part C program rule proposed
great thanks Chris question um do you think the current fee for service methodologies will deter the growth of AI or digital Health in certain aspects of healthcare do you anticipate any policy changes yeah I'll I'll I'll I'll think uh I'll talk kind of high level I think it's a great question very insightful I think when we think about Ai and the way that some are interpreting the use of AI is does it make a physician or healthc care provider's job easier and when we Think about how payment is set up they want to know how
hard is it how much time does it take and what's your overhead and so if we add a on to a on to the to the mix while there is a cost of overhead to provide the AI does it also decrease the cost of uh the total workload for a physician I don't think that there's a one- siiz fits-all in this determination I think Tanya brought up some great examples of where AI has been leveraged um thinking of shock cbel And some others where we didn't see actually an impact to the overall physician uh reimbursement
or total reimbursement and they were actually able to leverage and tap uh right and TPT to get additional payments so I think we might see a plus and a minus I don't know that there's a one-size fits-all I also don't think that we have um 100% knowledge but I would say I loved what Ryan said earlier is it's really understanding what is the Foundation of the technology how will we leverage this new a capability what does it add for overall you know physician work Health practice outcomes and then how do we monetize that how do
we understand the value if it decreases in one and gains in another my expectation is right there's probably room for a little bit of all uh AI won't completely replace the need of physician work but it might take down some of the burden and increase some of the outcomes and Then the you know the opportunity to add AI to that technology also has a practice expense to it so I think somewhere in the middle uh we would expect there to be some some great ways in which we should expect reimbursement to continue on and I
think that there's some precedence with um technologies that gone through this process and see policies come out and payments I think if we can use those as learning tools and leverage those with other Technologies it's a great way for us to help people be more successful or at least understand the landscape to be successful it's great thank you Kelly I love the questions they're coming in so um I'm going to read the next one verbatim it is for Chris um Chris with all the suggestions about taking the payer to alj have any of your clients
pursued legal action at the district SL local level or even considered a quam quam on behalf of the ma population or Enroles that is a super specific question uh and uh I I like that question a lot and spent a lot of time thinking about that so I'm going to try to carefully answer that in a way that isn't specific legal advice so the short answer is it's complicated um part of the reason it is complicated is because a lot of times the rights run with the beneficiary um so you'd be talking about coordinating with
the beneficiary in order to be able To try the case um the other thing that comes up is there is some some uh some precedent for attempting to sue payers over coverage decisions and I'm not aware of a lot of those going particularly great although I haven't done I haven't done a search of um I haven't done a case law search on that in a while so there there perhaps could be some movement um the idea of a keam is a very interesting idea uh but uh and one that I've Certainly thought about but goes
outside the scope of what we've talked about here but whoever wrote that question I like where your head's at I think that was Anonymous so perhaps they'll email you after or uh reach out so thanks for that question answer um next one in the instance of a potential soft denial would you advocate for the provider to submit a prior authorization anyway or apply a wait and see approach so I'd be happy to to kick this One off too um it really depends upon what the process at the individual payer is because if it's a if
it is a portal based process um there isn't really an opportunity to submit a prior authorization if um if they're saying they won't accept one now we had talked about it earlier that there are alternative proces that are available but those tend to be unique for the payer that's things like case consideration medical Exception like those kinds of things um and not a lot of those policies or procedures for getting those kinds of things are published so it's really something that um that you need to have some experience to navigate artfully and the reality is
you can call a payer and ask for a predetermination instead of a prior authorization you can call that payer four times talk to four different people and get four completely different answers about what they say You can do with that case so uh sometimes you just got to call and talk to the right person to get it entered into the system but yeah the answer is you have to fight for a way to get it in yeah I I go that definitely not the wait and see approach I think uh that right for most folks
they want to make sure that they've at least documented the efforts that have been put forth in order to get a medical review done and completed so I agree with Christopher it Can be a complex network but we would recommend absolutely trying to find a way I think it goes back to that Foundation of patient advocacy yeah and if I can just add to that briefly the part of the challenge is a lot of this depends upon what I think of as good fundamentals and like when when you look at a lot of where where
things are really moving in a way that's kind of disturbing in the industry and you look well what's the Answer to if all of a sudden Medicare becomes less of a problem what is the answer to if uh Medicare Advantage starts finding more ways to pull in commercial policies answer to a lot of those things is the same as it is for this which is good fundamentals where you build around a specific medical need and you address that medical need because if you're trying to ask for individual case consideration you're walking in there and you're
saying we Have a patient and they have a need and nothing out there fills this need so we need you to make an exception to your policy and the way you do that is by building off of the good fundamentals it's not a situation where you can just walk in and speak shith and they're like oh great we'll take the case um yeah you have to build that that strategy and that way of thinking around it yeah great great thoughts um speaking of Medicare next question uh Max or the Medicare administrative contractors are implementing their
own policies via LCDs as opposed to implementing CMS policies or national coverage decisions do we expect CMS to assert more policy control over uh via ncds going for I'd be I'd be happy to take that one um so probably not um because there aren't a lot of ncds that come out every year but what has been happening is an alternative Mac collaboration process And it's a situation where all the Macs or a group of Macs get together and um and start researching a topic and all come out with policies that look essentially the same now
the thing that's good about it is you can know what's going on in a whole bunch of places at the same time the bad part is that that collaboration part isn't really subject to process like an NCD or the individual LCDs are and now you can make the argument that when you get to The individual LCDs there's public participation in a public process there but if there's already been an agreement among all the Macs that this is what the policy is going to look like you're you're climbing a mountain to come up with a reason
why they should carve out and why things should be different for that particular local area yeah good point right along lines Chris if I might ask a question I mean i a Nuance to make clear for the audience is just that the Establishment of ncds or LCDs is is really more focused not necessarily on covering you know producing a new one for every new technology there there's got to be a triggering need for Medicare to produce something like that and I see this as sort of a question of like what would rise to the purview
of a Mac to write an LCD but not uh CMS to produce an n CD um and and then subsequent to That what would need to happen for it to then trigger the NCD Kelly did you want to add something yeah no I loved your question I think the thing to be thoughtful of is the why there's LCDs to start with and not everything's governed centrally and it's because we know that there's unique populations in unique geographies which is part of the reason why there's those carve out so that there's more Regional Trends can be
Tak into account when Regarding policies for Medicare right specifically uh right you can think of different areas that might include like Florida Arizona right might have different needs for their LCDs and what's happening in those populations very different than might what might be happening in say New York and so you see these carve outs to really maximize what's happening in these demographics to better match policies based on demographic need so to your point when We think about it from a national level we would be looking at something that would hit that National criteria when we
think about the majority of patients over the age of 65 and like the disease burden affecting right the majority versus unique uh example you know unique geographies so just thoughtful like why you say well this LCD did it and this one didn't and I love what Chris said about the Consortium we absolutely are seeing more of that we do like to see Right uh you know kind of uh medical directors looking together at group populations but just helpful for the audience to understand like why would I see something in one and not another and why
is there LCDs to start with it's really just understanding like what was the purpose of setting these up geographically and regionally to set up different policies I don't know Chris if you want to add anything to that but um just think it's helpful context yeah no I I I think it is and one of the the challenges that we come up against all the time is that the payer perspective is different from the industry perspective and Industry looks at Medical policies as this is something that's sales enabling for us and it absolutely is but that's
not payers make medical policies they make medical policies to have a consistent framework for attempting to make consistent decisions while managing utilization so If there isn't a perceived problem with utilization there's not going to be a policy and that applies to both Medicare and applies to commercial if if they're happy with how something's going they're not going to go out of their way and do all the work that it takes to make a policy because it's not free to make and maintain those things and if if you were to have a policy for all the
codes it just it doesn't work yeah that's those are great points um I love this next Question um and it's a kind of that one of the $64 million questions as they say um are RCT and comparative data a must to get a positive recommendation and medical policies and what is the average trial time requested 2 five 10 years follow on follow up finally the economic value messages are those beneficial in the US with the payers I know everybody's got something to say here I'll kick it off if that's okay With the team I'll just
say my experiences especially for medical Technologies rcts are hard randomizing something to write a surgery can be very difficult and so I would absolutely say it's not a must it is a nice to have but there is definitely additional clinical evidence that can help you communicate directly with the payer to show you know that you're reasonable you're necessary you're as good as what's being offered today um and sometimes even better but It doesn't necessarily have to be direct comparison data it doesn't necessarily have to be a randomized control trial it's really understanding what previous evidence
in your disease States also already exists and using some of that historical knowledge in order to create like a broader uh or more expansive way of thinking about your evidence when you ask about timelines how long two years 5 years 10 years the thing I always like to talk to uh folks about is well it Depends on your Market if we're talking about a commercial payer right who thinks maybe this patient will be with us from 3 to five years while 10 years worth of information would sound great they're really interested in that shorter term
and we'd make a lot of Headway however if you're Medicare Medicare Advantage these these members tend to take with those plans for over 10 years so long-term information is going to be super critical for them so It's understanding like which segment you're speaking to are you primarily a commercial Market are you a Medicare Market are you a Medicaid market and then understanding how does the different levels of uh evidence speak to each one of those both in time as well as comparison or you know uh outcomes data and then with regards to economics data there's
so many different ways to unwrap that right and so economics can be like the hard you know this is how Much costs this is how much we saved right uh but then there's other softer metrics where folks are saying less time in the hospital is economics right and so it's really understanding again who it is we need to make the economic presentation to if it's the economic presentation to the payer what are the direct costs that we then subtract from their total system if it's essentially a you know a hospital outcome then it might just
be the total cost of their Care and a savings methodology and so while I think healthcare economics messaging is absolutely critical it's understanding how do I set up that right messaging based on the stakeholder so I love this question uh big fan of talking about anything and how do we set up better evidence to speak to multiple stakeholders um what I hope you guys hear me say is that it's it there's unique ways to craft this especially medal device I think we talked to most Of uh our medical director friends here at Bria they would
absolutely love to make sure that everybody had an RCT or comparative data but it's absolutely not a musthave um and I think it's important to really help folks map out what it is we need who it is we're communicating with and that way we can get the right outcomes whether those be um economics or clinical outcomes so we have the right message yeah and and just to you know priia does um often we do evidence Generation planning for our clients because evidence is King and I would say that rcts um yes they're difficult and they're
not the only way though to get coverage any longer so you know real world data is very um very helpful and and that's often an Avenue as well um we have we are up on time um I know there's a few additional questions that we've received and I promise that we will get back to you offline uh with answers to those questions um May I just have each Of the panelists give one or two sentences to a part on the audience um kind of top of Mind words of wisdom for the um the attendees that
are here today and thank you again for everyone for attending Kelly want to start yeah absolutely first everybody so great spending time with you we look forward to hearing more questions and seeing how we can support you I think at the end of the day what I hope you heard us say is that um reimbursement is absolutely Ely A helpful Catalyst whether you're thinking about it from your commercial plan or even raising money with investors we want to help you think um both smarter about what is the evidence that you need to talk to multiple
stakeholders like we just talked about here and then how do we leverage all that information in terms of type of evidence how do we create a commercial plan what is the um advocacy roots that Garner the most amount of success and Put that into like a strategy and then we pressure test that strategy to make sure that we're getting the outcomes that we need I think it's important to have a good partner that really understands this as you guys can see in today's discussion sometimes um these things are all intertwined but also dealt with very
separately and so having somebody to help uh make clear what the global outcome that we're looking for is is going to be a critical part of being Successful moving forward so thank you absolutely agree thank you Kelly Tracy yeah um I'd like to say just planning your reimbursement strategy and Logistics around reimbursement hotline whether it's internal or outsourced with a company like priia as early as possible um that should be one of the fundamentals even before the the product comes to Market thank you Tracy Ryan um just to kind of build off of uh Traces
I think also you know when you're thinking about when to develop your reimbursement or just uh Market access strategy it's never too early to start thinking through that um and and as sort of a a cautionary analogy you can't just uh you know thinking like an engineer or a clinician look at it like the Field of Dreams analogy like if I build this cool widget surely there's a business model to build off of this like if you build It they will come it's not um how this works in this day and age and you really
got to focus on understanding who are the stakeholders especially the financial stakeholder what do they care about and be doing that in parallel with development of your product um because it's essential to um pivot early as opposed to later uh when it's more costly absolutely agree thank you Ryan Chris last thoughts yeah I like to to reiterate what Ryan's saying is that in In this time where where we're all looking like oh well there's all this regulatory change well what are we going to do with AI and we're trying to figure out all of these
things that at the end of the day the fundamentals are still really important and if you focus on Physicians wanting to use your product so that there's demand that's built into the system and you take a thoughtful approach to evidence development where where you do Try to get some meaningful end points and sometimes you can't do an RCT sometimes an RCT is unethical um and you need to be simultaneously working that same track and and trying to come up with that reasonable amount of evidence at the same time but if you have if you have
the physician demand and and Physicians and patients really want to use this because they perceive they're being an unmet need and you're on your way to proven that through outcomes that A whole lot of these other problems are much more addressable absolutely well thank you everyone thank you panelists for the um the great conversation and fantastic advice and perspectives uh we look forward to seeing you uh to seeing attendees on our next webinar thank you everyone for attending and have a great rest of your day thanks everyone